Drugmaker Amgen Inc is buying Five Prime Therapeutics for about $1.9 billion to expand its line of gastric cancer drug candidates and its presence in Asia-Pacific, the companies said on Thursday.
Amgen has been looking to grow in the oncology market in the region since gaining a toehold in China in 2019 through a 20.5% stake in cancer drugmaker BeiGene Ltd for nearly $3 billion. It expects the region to contribute about a quarter of its growth over the next 9-10 years.
Amgen said it will pay $38 per Five Prime share, representing a premium of nearly 79% to the company’s last closing price of $21.26.
Read more at: Reuters
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.